about
Idiopathic CD4+ lymphocytopenia: natural history and prognostic factorsComparison of the Abbott 7000 and Bayer 340 Systems for Measurement of Hepatitis C Virus LoadHepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell CountsHIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders DoART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremiaFailure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosisAssociation of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV.Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection.Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDSTwice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapyEffects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics.Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptaseImpact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients.A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients.Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIVNew real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatmentHIV populations are large and accumulate high genetic diversity in a nonlinear fashionIdentification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach.Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapyHuman immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells.Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.Promising new treatments for cytomegalovirus retinitis.Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion.Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen.HIV Infection, hepatitis C infection, and HAART: hard clinical choices.High interferon-stimulated gene ISG-15 expression affects HCV treatment outcome in patients co-infected with HIV and HCV.HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals.Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
P50
Q24648099-6F436EEB-4697-4F4C-907A-15D4F2CFC7CAQ27481437-2DA1DBAA-3CB3-4785-95D6-0C2B5B5EC136Q27490439-5BD7B8D8-2A90-49F3-ABB2-850AD7C8605EQ27491342-EA6CEBA4-E5C8-45B5-88FD-4D56FACC4145Q28469175-09A00211-5474-4EE9-8770-BA55B7DBD846Q28483770-D70E0E3E-091F-49C6-AAFA-3AB7C7E53E9AQ33588960-E1AAD882-223A-4FED-9CD6-BD6FB286E375Q33889225-1B701CB6-2EFA-43FB-B9AD-4B6960AE87D0Q33895698-07721FD4-801D-44F9-8F15-336C1DDC29E8Q33916321-8282E557-BD63-4E05-9FD8-D85C05D160C6Q33924165-3A0FA62F-C7D6-4FB8-BD3E-61B5511708B1Q33980263-6FC405C3-B5DA-4796-99DB-890B914258ABQ33999004-720F8248-CFAA-44EE-B2C9-EC24ABC7B469Q34066537-3D394482-94BB-42DF-9822-F6E0CE84D410Q34075725-281D8C27-A3C5-4786-AC4B-F4CA4D3273EFQ34431819-44C25BA1-2FD1-4DBE-AB4E-33841E4E91F9Q34435083-5EB43BA1-9BE4-49A6-9042-E25F38FF797DQ34624732-CCB8939F-DB93-4C8E-B56B-8BEB0137531FQ34673075-970AB4AB-A5FB-4A5D-B7D9-A2EE91DDED34Q35992420-510449AC-B2FC-4F4D-990E-1E0A23A85559Q36369802-36DADDDA-2ABB-4267-A455-E8F7857E9A7DQ36891848-5018ED91-7E54-4EDE-990B-457D13DCBD0DQ36949481-0003C475-98D4-47D5-A2EA-C811E8F5ADA6Q36974934-F9C21BA8-E8CB-4DFE-92BE-E6CA1158183AQ37123158-2A4EDCF5-1925-4CD1-A8FE-A946CFCD8B78Q37124586-EF695CBD-5B76-442A-A634-E84C2C163D4DQ37207042-98E9BE35-CC87-41ED-889E-8E906E1A62DBQ37328900-D7054FD8-1E2F-4491-BFE0-19CDEBFE2D66Q39325002-4BB5FF52-8BF3-43E8-90FF-F3C1A5DD90CBQ39943264-42EADACA-BEE8-4867-A78A-C7CD466EBACEQ40509783-6DB163F1-AFC2-4754-A17A-01A8777F3BC2Q40662225-EC0B73E4-25DC-4578-9678-4CD99C2D2CEDQ40715387-745AC4A2-CFA5-4EEA-81E6-0A764F6A597BQ41539359-9A690B57-22AD-48E0-829E-04EFE9A080BCQ42445602-04EE0F95-4C82-4483-A774-429B14BEB3DAQ42602042-C4ADEA14-55AF-40AF-9360-FAB0AB63BF9FQ42986303-96EBE1A8-8725-47D0-BE50-328841BF2003Q42991216-AD97E9B9-2D8E-408C-9E79-C91B9106F250Q43000923-E94ECA84-8826-46E0-ABB5-CE3F04B1FB8EQ43040277-7E0E4186-DE1E-4B1A-BA98-6514CB0685B1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael A Polis
@es
Michael A Polis
@nl
Michael A Polis
@sl
Michael A. Polis
@en
type
label
Michael A Polis
@es
Michael A Polis
@nl
Michael A Polis
@sl
Michael A. Polis
@en
prefLabel
Michael A Polis
@es
Michael A Polis
@nl
Michael A Polis
@sl
Michael A. Polis
@en
P106
P1153
7004813105
P21
P31
P496
0000-0002-9151-2268